Howard Mayer - 16 Jul 2021 Form 4 Insider Report for Entasis Therapeutics Holdings Inc.

Role
Director
Signature
Elizabeth M. Keiley as Attorney-in-Fact for Howard Mayer
Issuer symbol
N/A
Transactions as of
16 Jul 2021
Net transactions value
$0
Form type
4
Filing time
15 Feb 2022, 15:03:11 UTC
Next filing
05 Aug 2021
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ETTX Stock Option (Right to Buy) Disposed to Issuer -15,000 -100% 0 16 Jul 2021 Common Stock 15,000 $6.44 Direct F1, F2
transaction ETTX Stock Option (Right to Buy) Award +12,500 12,500 16 Jul 2021 Common Stock 12,500 $2.44 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option provided for vesting as follows: The shares subject to this option will vest in equal monthly installments over the three years following the date of grant, subject to the Reporting Person's continued service through each such vesting date.
F2 On July 16, 2021, the issuer canceled, pursuant to the issuer's option exchange program, an option for 15,000 shares of issuer's common stock granted to the Reporting Person on August 5, 2019. In exchange, the Reporting Person received a replacement option for 12,500 shares of issuer's common stock, having an exercise price of $2.44 per share.
F3 Seventy-three (73%) of this award will vest on July 16, 2022, and one-thirteenth of the remaining shares subject to the option will vest monthly following July 16, 2022, subject to the Reporting Person's continuing to provide service through each such date.